Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
The significant tumor shrinkage and immunologic changes observed support a complementary role of SBRT and PD-1 immunotherapy, investigators concluded.
Circulating tumor DNA can help differentiate pseudoprogression from true progression in patients with melanoma who are treated with PD-1 inhibitors.
Patients with ER-negative, but not ER-positive, isolated locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.
A retrospective review found that obesity is associated with improved progression-free and overall survival in certain patients with metastatic melanoma.
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.
Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.
An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.
A phase II trial found that the immune checkpoint inhibitor durvalumab has promising clinical activity and is well tolerated both as monotherapy and in combination with tremelimumab in patients with heavily pretreated recurrent or metastatic head and neck cancer, whose tumors are PD-L1 low or negative.